These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1681376)

  • 41. HCV infection in patients with primary defects of immunoglobulin production.
    Quinti I; Pandolfi F; Paganelli R; el Salman D; Giovannetti A; Rosso R; Oliva A; Rainaldi L; Aiuti F
    Clin Exp Immunol; 1995 Oct; 102(1):11-6. PubMed ID: 7554376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HCV and Gammagard in France.
    Gomperts ED
    Lancet; 1994 Jul; 344(8916):201. PubMed ID: 7912801
    [No Abstract]   [Full Text] [Related]  

  • 43. [Hepatitis C; current developments in diagnosis and therapy].
    Willems M; Moshage H; Fevery J; Yap SH
    Ned Tijdschr Geneeskd; 1992 Dec; 136(52):2564-7. PubMed ID: 1282675
    [No Abstract]   [Full Text] [Related]  

  • 44. Viral transmission by blood products: a perspective of events covered by the recent tribunal of enquiry into the Irish Blood Transfusion Board.
    Yap PL
    Ir Med J; 1997; 90(3):84, 86, 88. PubMed ID: 9183082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic haemodialysis patients: a study with second-generation assays.
    Fabrizi F; Raffaele L; Bacchini G; Guarnori I; Pontoriero G; Erba G; Locatelli F
    Nephrol Dial Transplant; 1993; 8(8):744-7. PubMed ID: 7692356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow's ophthalmopathy treated with intravenous immunoglobulins].
    Antonelli A; Neri S; Gasperini L; Alberti B; Saracino A; Gambuzza C; Agostini S; Baschieri L
    Clin Ter; 1992 Sep; 141(9 Pt 2):55-61. PubMed ID: 1468200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anti-hepatitis C viral antibodies in different pathological entities in Chile].
    Velasco M; Hurtado C; Brahm J
    Rev Med Chil; 1990 Aug; 118(8):895-6. PubMed ID: 1967082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C and injecting drug use in prisons.
    McBride AJ; Ali IM; Clee W
    BMJ; 1994 Oct; 309(6958):876. PubMed ID: 7524876
    [No Abstract]   [Full Text] [Related]  

  • 49. Infectious risk of plasma donations: relationship to safety of intravenous immune globulins.
    Dodd RY
    Clin Exp Immunol; 1996 May; 104 Suppl 1():31-4. PubMed ID: 8625541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of non-A,non-B hepatitis/hepatitis C virus antibody in human immunoglobulins.
    Dodd LG; McBride JH; Gitnick GL; Howanitz PJ; Rodgerson DO
    Am J Clin Pathol; 1992 Jan; 97(1):108-13. PubMed ID: 1728850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anti-HCV test in patients with chronic non-A, non-B hepatitis].
    Havelka J; Zala G; Joller-Jemelka HJ; Altorfer J; Meier B; Schmid M; Bühler H
    Schweiz Med Wochenschr; 1992 Feb; 122(6):198-200. PubMed ID: 1311126
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence of antibodies to hepatitis C virus in a chronic hemodialysis population.
    Carrera F; Silva JG; Oliveira C; Frazao JM; Pires C
    Nephron; 1994; 68(1):38-40. PubMed ID: 7527504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous immune globulin in primary immunodeficiency.
    Haeney M
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):11-5. PubMed ID: 8033427
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hepatitis C antibodies in children and adolescents with congenital blood coagulation disorders].
    Zenz W; Hofmann H; Muntean W
    Wien Klin Wochenschr; 1991; 103(3):69-72. PubMed ID: 1851352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of intravenous immunoglobulin with regard to hepatitis C virus.
    Yu MW; Mason BL; Guo ZP; Tankersley DL
    Clin Ther; 1996; 18 Suppl B():71-2. PubMed ID: 8930443
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection.
    Orloff SL; Stempel CA; Wright TL; Tomlanovich SJ; Amend WJ; Stock PG; Melzer JS; Vincenti F
    Clin Transplant; 1995 Apr; 9(2):119-24. PubMed ID: 7599400
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis.
    Ramsay I; Gorton RL; Patel M; Workman S; Symes A; Haque T; Irish D; Seneviratne SL; Burns SO; Wey E; Lowe DM
    Clin Infect Dis; 2016 Jul; 63(1):57-63. PubMed ID: 27076567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expanding organ availability by using hepatitis C antibody positive donors.
    Aswad S; Mendez R; Weingart RG; Mendez R
    Transplant Proc; 1993 Jun; 25(3):2270-1. PubMed ID: 7685947
    [No Abstract]   [Full Text] [Related]  

  • 59. [The frequency of antibodies against delta virus in patients with HBs positive hepatitis].
    Ivaniushina VA; Ryzhova EV; Grudinin MP; Katorgina LG; Nikonova AN; Vinogradova EN; Iakovlev AA
    Vopr Virusol; 1996; 41(4):166-9. PubMed ID: 8999671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Role of hepatitis C virus in the genesis of hepatic lesions observed in alcoholic patients with liver cirrhosis].
    Deny P; Halimi C; Trinchet JC; Munz C; Bianchi A; Mal F; Beaugrand M
    Gastroenterol Clin Biol; 1994; 18(2):110-4. PubMed ID: 7516902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.